

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,835	02/05/2004	Corinne Gail Wong	UCIVN-003C	7175
75	90 01/28/2005		EXAM	INER
Robert D. Buyan			AZPURU, CARLOS A	
STOUT, UXA,	BUYAN & MULLINS,	LLP		
Suite #310			ART UNIT	PAPER NUMBER
4 Venture			1615	
Irvine, CA 92618			DATE MAILED: 01/28/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/773,835	WONG ET AL.				
Office Action Summary	Examiner	Art Unit				
	Carlos A. Azpuru	1615				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
2a) This action is FINAL . 2b) ⊠ Thi	This action is FINAL . 2b)⊠ This action is non-final.					
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-98</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
	6) Claim(s) 1-98 is/are rejected.					
	7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on $02/05/2004$ is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s) 1) Notice of References Cited (RTO 802)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	4)				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal Pa	atent Application (PTO-152)				

Application/Control Number: 10/773,835

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of the information disclosure statement filed 05/03/2004. A preliminary amendment was filed on 11/04/2004.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1, 3-34 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 3-34. of prior U.S. Patent No. 6,692,759. This is a double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Application/Control Number: 10/773,835

Art Unit: 1615

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 35-98 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-34 of U.S. Patent No. 6,692,759 (US'759). Although the conflicting claims are not identical, they are not patentably distinct from each other because US'759 claims a method of preparing an implantable device for sustained delivery of a chemical substance comprising dissolving a biocompatible polymer in a suitable solvent. adding the chemical substance, drying and then adding a liquid to soften the mass and then mold it into a desired shape (see claims 1 and 2). Addition of a second polymer-solvent solution-substance admixture made by steps (A) and (B) is added to said substantially dry mass of said step (C) is set out in claim 3. A method for using an implantable device to introduce it into the body and release a biological substance is set out in claim 25. Therefore, those of ordinary skill would have expected similar therapeutic results from the instantly claimed methods and delivery device given the claims of US'759 which set out a similar methods and device. As such, the instant claims would have been obvious given the claims of US'759.

Claims 1, 2, 4, 5, 7-10, 13-15, 26, 30, 34, 35, 36, 38, 39, 41-44, 45, 48, 49, 62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Donovan.

Donovan discloses an implant and method of preparing said implant by dissolving a biocompatible polymer, adding a substance, drying said polymer-

Page 4

Application/Control Number: 10/773,835

Art Unit: 1615

solvent solution-substance admixture, then refrigerating said dry mass. (see col. 2, lines 42-51; col. 8, lines 35-56; col. 14, lines 45-47; col. 15, lines 34; col. 20, lines 25-50; column 23, lines 50-55; col. 25, line 15). Addition of a liquid is implied through the disclosure of using a hydrogel at col. 2, lines 52-54.

Manipulation of the softened mass to form microcapsules is also disclosed at col. 20, lines 62-67; col. 21, lines 1-2. Those of ordinary skill would expect the same therapeutic results and pharmacological characteristics from the instant invention given the teachings of Donovan which include refrigeration of the dry solvent/polymer/substance mass, as well as addition of a liquid to said mass to form a hydrogel. Therefore, it would have been obvious to claim the instant method for preparing an implantable device by refrigerating the polymer/solvent/substance mass and or add liquid given the teachings of Donovan.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ca

PRIMARY EXAMINER
GROUP 1500